234 related articles for article (PubMed ID: 29330561)
1. Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Fouquet G; Karlin L; Macro M; Caillot D; Roussel M; Arnulf B; Pegourie B; Petillon MO; Mathiot C; Hulin C; Kolb B; Stoppa AM; Brechiniac S; Rodon P; Dib M; Tiab M; Richez V; Araujo C; Wetterwald M; Garderet L; Royer B; Perrot A; Benboubker L; Decaux O; Escoffre-Barbe M; Fermand JP; Moreau P; Avet-Loiseau H; Attal M; Facon T; Leleu X
Ann Hematol; 2018 May; 97(5):831-837. PubMed ID: 29330561
[TBL] [Abstract][Full Text] [Related]
2. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Morgan G; Palumbo A; Dhanasiri S; Lee D; Weisel K; Facon T; Delforge M; Oriol A; Zaki M; Yu X; Sternas L; Jacques C; Akehurst R; Offner F; Dimopoulos MA
Br J Haematol; 2015 Mar; 168(6):820-3. PubMed ID: 25403264
[TBL] [Abstract][Full Text] [Related]
3. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.
Leleu X; Karlin L; Macro M; Hulin C; Garderet L; Roussel M; Arnulf B; Pegourie B; Kolb B; Stoppa AM; Brechiniac S; Marit G; Thielemans B; Onraed B; Mathiot C; Banos A; Lacotte L; Tiab M; Dib M; Fuzibet JG; Petillon MO; Rodon P; Wetterwald M; Royer B; Legros L; Benboubker L; Decaux O; Escoffre-Barbe M; Caillot D; Fermand JP; Moreau P; Attal M; Avet-Loiseau H; Facon T;
Blood; 2015 Feb; 125(9):1411-7. PubMed ID: 25575538
[TBL] [Abstract][Full Text] [Related]
4. Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y; Kuroda J; Kaneko H; Kamitsuji Y; Fuchida SI; Nakaya A; Shibayama H; Uoshima N; Yokota I; Uchiyama H; Yagi H; Kosugi S; Matsui T; Ishikawa J; Matsuda M; Ohta K; Iida M; Tanaka H; Kobayashi M; Wada K; Shimazaki C; Nomura S; Imada K; Hino M; Matsumura I; Kanakura Y; Takaori-Kondo A;
Int J Hematol; 2018 May; 107(5):541-550. PubMed ID: 29380179
[TBL] [Abstract][Full Text] [Related]
5. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials.
Zou Y; Ma X; Yu H; Hu C; Fan L; Ran X
Oncotarget; 2017 Jun; 8(24):39805-39817. PubMed ID: 27458170
[TBL] [Abstract][Full Text] [Related]
7. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial.
Weisel K; Dimopoulos M; Song KW; Moreau P; Palumbo A; Belch A; Schey S; Sonneveld P; Sternas L; Yu X; Amatya R; Gibson CJ; Zaki M; Jacques C; San Miguel J
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):519-30. PubMed ID: 26149712
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M
Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Cohen A; Spektor TM; Stampleman L; Bessudo A; Rosen PJ; Klein LM; Woliver T; Flam M; Eshaghian S; Nassir Y; Maluso T; Swift RA; Vescio R; Berenson JR
Br J Haematol; 2018 Jan; 180(1):60-70. PubMed ID: 29164606
[TBL] [Abstract][Full Text] [Related]
10. Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
Richardson PG; Attal M; Campana F; Le-Guennec S; Hui AM; Risse ML; Corzo K; Anderson KC
Future Oncol; 2018 May; 14(11):1035-1047. PubMed ID: 29268619
[TBL] [Abstract][Full Text] [Related]
11. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
[TBL] [Abstract][Full Text] [Related]
12. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
[TBL] [Abstract][Full Text] [Related]
13. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
San Miguel JF; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Renner C; Bahlis NJ; Yu X; Teasdale T; Sternas L; Jacques C; Zaki MH; Dimopoulos MA
Haematologica; 2015 Oct; 100(10):1334-9. PubMed ID: 26160879
[TBL] [Abstract][Full Text] [Related]
14. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.
Ailawadhi S; Mikhael JR; LaPlant BR; Laumann KM; Kumar S; Roy V; Dingli D; Bergsagel PL; Buadi FK; Rajkumar SV; Fonseca R; Gertz MA; Kapoor P; Sher T; Hayman SR; Stewart AK; Dispenzieri A; Kyle RA; Gonsalves WI; Reeder CB; Lin Y; Go RS; Leung N; Kourelis T; Lust JA; Russell SJ; Chanan-Khan AA; Lacy MQ
Leukemia; 2018 Mar; 32(3):719-728. PubMed ID: 28860655
[TBL] [Abstract][Full Text] [Related]
15. Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Hoy SM
Drugs; 2017 Nov; 77(17):1897-1908. PubMed ID: 29110190
[TBL] [Abstract][Full Text] [Related]
16. Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Weisel KC; Dimopoulos MA; Moreau P; Lacy MQ; Song KW; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Knop S; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel J
Haematologica; 2016 Jul; 101(7):872-8. PubMed ID: 27081177
[TBL] [Abstract][Full Text] [Related]
17. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.
Ríos-Tamayo R; Martín-García A; Alarcón-Payer C; Sánchez-Rodríguez D; de la Guardia AMDVD; García Collado CG; Jiménez Morales A; Jurado Chacón M; Cabeza Barrera J
Drug Des Devel Ther; 2017; 11():2399-2408. PubMed ID: 28860711
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.
Spencer A; Harrison S; Zonder J; Badros A; Laubach J; Bergin K; Khot A; Zimmerman T; Chauhan D; Levin N; MacLaren A; Reich SD; Trikha M; Richardson P
Br J Haematol; 2018 Jan; 180(1):41-51. PubMed ID: 29076150
[TBL] [Abstract][Full Text] [Related]
19. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
20. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Moreau P; Weisel KC; Song KW; Gibson CJ; Saunders O; Sternas LA; Hong K; Zaki MH; Dimopoulos MA
Leuk Lymphoma; 2016 Dec; 57(12):2839-2847. PubMed ID: 27173785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
